Published by Bloomberg Article 4/19/21 https://ww
Post# of 155600
(Total Views: 481)
Posted On: 04/27/2021 11:31:55 PM
Published by Bloomberg Article 4/19/21
https://www.bloomberg.com/press-releases/2021...csp-in-the
I frequent 4 CYCY discussion forums, had not seen this Bloomberg article until today. (Nader announced the leronlimab was given to Pres Estrada)
Former President of the Philippines, Joseph Estrada, Among the Many COVID-19 Patients Receiving Leronlimab Under CSP in the Philippines
CytoDyn is following all patients treated with leronlimab under CSP and will
provide additional information when available and authorized for release
VANCOUVER, Washington, April 19, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc.(OTC.QB: CYDY), (“CytoDyn” or the “Company"
, a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with potential multiple therapeutic indications, announced today former President of the Philippines, Joseph Estrada, was administered leronlimab under Compassionate Special Permit (CSP), among other medication, as a therapeutic for COVID-19. Mr. Estrada remains hospitalized and news reports indicate he may be transferred from ICU to a regular hospital room soon. CytoDyn continues to ship vials of leronlimab to the Philippines, while its distribution partner, Chiral Pharma Corporation, works closely with the Philippine FDA to consider expanding the CSP.
Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn, commented, “We have been working with Chiral Pharma for several months to provide COVID-19 patients in the Philippines access to leronlimab under CSP.
CytoDyn is grateful for the opportunity to help the former President and his
family and we wish him a full and speedy recovery. While we pursue emergency use authorizations in many countries and initiate final trials for the severe and critical COVID-19 patient populations to strengthen these applications, our teams remain hopeful their dedication and efforts will help COVID-19 patients around the world. We also are happy to report our BLA resubmission for HIV is on track and we are encouraged with the advancements in our expanding cancer program. I look forward to providing a full update to all of our stakeholders soon.”
https://www.bloomberg.com/press-releases/2021...csp-in-the
I frequent 4 CYCY discussion forums, had not seen this Bloomberg article until today. (Nader announced the leronlimab was given to Pres Estrada)
Former President of the Philippines, Joseph Estrada, Among the Many COVID-19 Patients Receiving Leronlimab Under CSP in the Philippines
CytoDyn is following all patients treated with leronlimab under CSP and will
provide additional information when available and authorized for release
VANCOUVER, Washington, April 19, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc.(OTC.QB: CYDY), (“CytoDyn” or the “Company"
, a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with potential multiple therapeutic indications, announced today former President of the Philippines, Joseph Estrada, was administered leronlimab under Compassionate Special Permit (CSP), among other medication, as a therapeutic for COVID-19. Mr. Estrada remains hospitalized and news reports indicate he may be transferred from ICU to a regular hospital room soon. CytoDyn continues to ship vials of leronlimab to the Philippines, while its distribution partner, Chiral Pharma Corporation, works closely with the Philippine FDA to consider expanding the CSP. Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn, commented, “We have been working with Chiral Pharma for several months to provide COVID-19 patients in the Philippines access to leronlimab under CSP.
CytoDyn is grateful for the opportunity to help the former President and his
family and we wish him a full and speedy recovery. While we pursue emergency use authorizations in many countries and initiate final trials for the severe and critical COVID-19 patient populations to strengthen these applications, our teams remain hopeful their dedication and efforts will help COVID-19 patients around the world. We also are happy to report our BLA resubmission for HIV is on track and we are encouraged with the advancements in our expanding cancer program. I look forward to providing a full update to all of our stakeholders soon.”
(3)
(0)